Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Apipe vs Abilify (Aripiprazole) in Healthy Volunteers
NCT05804721Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole in schizophrenia and bipolar disorder (BD) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to 72 hours. Started Oct 2022; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT05804721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804721.